Arthritis & Rheumatology最新文献_第10页

Clinical Connections 临床联系

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-24 DOI: 10.1002/art.42603

引用次数: 0

Journal Club 期刊俱乐部

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-24 DOI: 10.1002/art.42601

引用次数: 0

Gout Flares As Vascular Red Flags 痛风发作是血管的红色警报

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-23 DOI: 10.1002/art.43015

Mariano Andrés

引用次数: 0

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti‐rheumatic drugs on pain reduction in rheumatoid arthritis 类风湿性关节炎患者服用破伤风激酶抑制剂和生物制剂改变病情抗风湿药物对减轻疼痛的效果比较

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-23 DOI: 10.1002/art.43014

Anna Eberhard, Daniela Di Giuseppe, Johan Askling, Stefan Bergman, Hannah Bower, Katerina Chatzidionysiou, Helena Forsblad‐d'Elia, Alf Kastbom, Tor Olofsson, Thomas Frisell, Carl Turesson

{"title":"Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti‐rheumatic drugs on pain reduction in rheumatoid arthritis","authors":"Anna Eberhard, Daniela Di Giuseppe, Johan Askling, Stefan Bergman, Hannah Bower, Katerina Chatzidionysiou, Helena Forsblad‐d'Elia, Alf Kastbom, Tor Olofsson, Thomas Frisell, Carl Turesson","doi":"10.1002/art.43014","DOIUrl":"https://doi.org/10.1002/art.43014","url":null,"abstract":"ObjectiveTo compare the effectiveness of Janus kinase inhibitors (JAKis) and biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) on pain in patients with rheumatoid arthritis (RA).MethodsIn this retrospective study, we investigated patients with a diagnosis of RA, starting treatment with a JAKi (n=1827), TNF inhibitor (TNFi, n=6422), IL‐6 inhibitor (n=887), abatacept (n=1102) or rituximab (n=1149) in 2017‐2019, using data from several linked Swedish national registers. Differences in change in pain, assessed with a visual analogue scale (VAS; 0‐100 mm), from baseline to 3 months, as well as proportions of patients remaining on initial treatment with low pain (VAS pain <20) at 12 months, were compared between treatments. Comparisons of treatment responses between JAKis and bDMARDs were evaluated using multivariable linear regression, adjusted for patient characteristics, comorbidities, current co‐medication and previous treatment.ResultsJAKi treatment was associated with a greater decrease in pain at 3 months compared with TNFi treatment (adjusted mean additional decrease: 4.0 mm; 95% confidence interval (CI) 1.6, 6.3), with similar trends in comparisons with non‐TNFi bDMARDs. More patients achieved low pain at 12 months on JAKis compared with TNFis, in particular among those previously treated with ≥2 bDMARDs (adjusted change contrast: 5.3 percentage points; 95% CI 1.0, 9.6).ConclusionJAKis had a slightly better effect on pain outcomes at 3 and 12 months compared with TNFis, with significantly greater differences in patients previously treated with ≥2 bDMARDs. The effect of JAKis on pain reduction was at least similar to that of non‐TNFi bDMARDs.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"5 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Images: Erdheim-Chester disease presenting with palpitations and spondylopathy. 埃尔德海姆-切斯特氏病伴有心悸和脊柱病。

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-23 DOI: 10.1002/art.43016

Xiang Li, Chun Wang

引用次数: 0

Strength Training Associates with Less Symptom and Structure Outcomes for Knee Osteoarthritis. 力量训练有助于减轻膝关节骨性关节炎的症状并改善其结构。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-19 DOI: 10.1002/art.42994

Grace H Lo,Jeffrey B Driban

引用次数: 0

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study. 活动性轴性脊柱关节炎患者静脉注射塞库单抗的疗效和安全性：随机、安慰剂对照、III 期 INVIGORATE-1 研究的结果。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-19 DOI: 10.1002/art.42993

Atul Deodhar,Jerzy Supronik,Alan Kivitz,Guillermo Valenzuela,Karen Kapur,Susanne Rohrer,Eva Dokoupilova,Hanno B Richards,Karel Pavelka

{"title":"Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study.","authors":"Atul Deodhar,Jerzy Supronik,Alan Kivitz,Guillermo Valenzuela,Karen Kapur,Susanne Rohrer,Eva Dokoupilova,Hanno B Richards,Karel Pavelka","doi":"10.1002/art.42993","DOIUrl":"https://doi.org/10.1002/art.42993","url":null,"abstract":"OBJECTIVETo assess the efficacy and safety of intravenous (IV) secukinumab for the treatment of adults with active axial spondyloarthritis (axSpA) in INVIGORATE-1.METHODSINVIGORATE-1 (NCT04156620) was a randomized, double-blind, parallel-group, phase III trial in patients with active axSpA (either radiographic or non-radiographic). Patients were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every 4 weeks) or IV placebo for 16 weeks. After Week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg every 4 weeks), while patients randomized to secukinumab continued treatment through Week 52. The primary endpoint was Assessment of SpondyloArthritis international Society (ASAS40) response at Week 16. Safety was evaluated through Week 60.RESULTSAmong patients initially randomized to IV secukinumab (n = 264) or placebo (n = 262), 86.0% and 88.9% completed the entire 60-week study period, respectively. A higher proportion of patients receiving secukinumab vs placebo met the primary endpoint (ASAS40 response) at Week 16 (40.9% vs 22.9%; P<.0001). By Week 24, patients who switched from placebo to secukinumab at Week 16 achieved ASAS40 response rates comparable to those in patients originally randomized to secukinumab. All secondary efficacy endpoints were met at Week 16, and responses were sustained through Week 52. No new or unexpected safety signals were observed with IV secukinumab.CONCLUSIONIV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. The safety profile was consistent with that in previous reports on subcutaneous secukinumab.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"45 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled Phase III INVIGORATE-2 Study. 静脉注射塞库单抗治疗活动性银屑病关节炎的有效性和安全性：随机、安慰剂对照的III期INVIGORATE-2研究结果。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-19 DOI: 10.1002/art.42997

Alan Kivitz,Liliana Sedova,Melvin Churchill,Roshan Kotha,Atul Singhal,Alexander Torres,Guillermo Valenzuela,Sarah Whelan,Thomas Dumortier,Xuan Zhu,Ruvie Martin,Luminita Pricop

{"title":"Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled Phase III INVIGORATE-2 Study.","authors":"Alan Kivitz,Liliana Sedova,Melvin Churchill,Roshan Kotha,Atul Singhal,Alexander Torres,Guillermo Valenzuela,Sarah Whelan,Thomas Dumortier,Xuan Zhu,Ruvie Martin,Luminita Pricop","doi":"10.1002/art.42997","DOIUrl":"https://doi.org/10.1002/art.42997","url":null,"abstract":"OBJECTIVETo evaluate the efficacy and safety of intravenous (IV) secukinumab in patients with active psoriatic arthritis (PsA).METHODSINVIGORATE-2 (NCT04209205) is a randomized, placebo-controlled, phase III trial. Patients with active PsA were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every 4 weeks [q4w]) or placebo. At Week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg q4w), and patients receiving IV secukinumab continued treatment through Week 52. The primary efficacy endpoint was achievement of American College of Rheumatology (ACR) 50 response at Week 16. Efficacy and safety were evaluated through Weeks 52 and 60, respectively.RESULTSAmong 191 patients randomized to IV secukinumab and 190 to placebo/IV secukinumab, 177 (92.7%) and 170 (89.5%) completed the entire study period, respectively. A significantly higher proportion of patients receiving IV secukinumab vs placebo achieved ACR50 at Week 16 (31.4% vs 6.3%; adjusted P<.0001). All secondary efficacy endpoints were met at Week 16 (all adjusted P<.05 using the predefined hypothesis-testing hierarchy). Patients who switched from placebo to secukinumab at Week 16 showed rapid improvements in ACR50 response rates; by Week 52, both treatment arms experienced similar improvements in efficacy outcomes. No new or unexpected safety signals were observed with IV secukinumab. One death was reported in the placebo group prior to Week 16.CONCLUSIONIV secukinumab led to rapid and sustained improvements in clinical measures of PsA, and the safety profile was consistent with that of secukinumab administered subcutaneously.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"63 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strength Training Is Associated With Less Knee Osteoarthritis: Data From the Osteoarthritis Initiative: comment on the article by Lo et al. 力量训练与减少膝骨关节炎有关：骨关节炎倡议的数据：对Lo等人文章的评论

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-19 DOI: 10.1002/art.42995

Yuncheng Bai,Yang Wu,Ge Wang

引用次数: 0

Weight loss after initiating anti-obesity medications and gout among overweight and obesity individuals: a population-based cohort study. 超重和肥胖者服用抗肥胖药物后体重减轻与痛风：一项基于人群的队列研究。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2024-09-19 DOI: 10.1002/art.42996

Jie Wei,Yilun Wang,Nicola Dalbeth,Junqing Xie,Jing Wu,Chao Zeng,Guanghua Lei,Yuqing Zhang

{"title":"Weight loss after initiating anti-obesity medications and gout among overweight and obesity individuals: a population-based cohort study.","authors":"Jie Wei,Yilun Wang,Nicola Dalbeth,Junqing Xie,Jing Wu,Chao Zeng,Guanghua Lei,Yuqing Zhang","doi":"10.1002/art.42996","DOIUrl":"https://doi.org/10.1002/art.42996","url":null,"abstract":"OBJECTIVESWeight loss is conditionally recommended for gout management; however, its impact on incident gout and recurrent gout flares among overweight and obese individuals remains unknown. We aimed to investigate the relationship between weight loss rate following the initiation of anti-obesity medications and the risk of incident gout and recurrent gout flares among overweight/obese individuals.METHODSUsing data from The Health Improvement Network, we selected individuals aged 18 and older who were overweight or obese and started anti-obesity medication. We emulated a target trial to examine the association of different weight loss rates, slow (2-5%), moderate (5-10%), or fast (≥10%), within the first year of treatment with incident gout and recurrent gout flares during a 5-year follow-up period.RESULTSAmong 131,000 participants without gout starting orlistat, the 5-year risk of incident gout was 1.6% for those with weight gain/stable, compared with 1.5%, 1.3%, and 1.2% for those with slow, moderate, and fast weight loss, respectively. Compared with the weight gain/stable arm, the hazard ratios were 0.91 (95% confidence interval [CI]: 0.81 to 1.01), 0.82 (95%CI: 0.72 to 0.92), and 0.73 (95%CI: 0.62 to 0.86) for slow, moderate and fast rate of weight loss arms, respectively. Similar results were observed for the recurrent gout flares among 3,847 overweight or obese individuals with gout starting orlistat.CONCLUSIONSA higher rate of weight loss after initiating orlistat within 1-year was associated with lower risks of incident gout and lower rates of recurrent gout flares among overweight or obese people.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0